Oncology

T cells attack a cancer cell
#Financing #Grey Wolf Therapeutics #Immuno-oncology #Investment #Oncology #T cell activation

$49 million raised to fund original immuno-oncology approach

Grey Wolf Therapeutics has closed an oversubscribed $49 million Series B financing co-led by Pfizer Ventures and Earlybird Venture Capital, with investment from Oxford Science Enterprises, British Patient Capital, Canaan and Andera Partners.   Proceeds will support the continued development of the company’s first-of-its-kind immuno-oncology approaches designed to overcome key resistance… Read More

#Business & Investment #News #Start-up Zone

Non-small cell lung cancer
#Biomarkers #Lung cancer #Merck #Oncology #Phase II trial #Precision medicine #Regulatory #Scottish Medicines Consortium (SMC)

SMC approves targeted treatment for lung cancer

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.  … Read More

#News #Regulatory

#AI / data analytics / healthtech / informatics #Cell and gene therapy #Magazine #Oncology #SLAS2023

DDW Winter issue out now

The Winter 2022/2023 issue of Drug Discovery World Magazine is out now. Featuring a Therapeutic Spotlight on Oncology, the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Read More

#Editor's Choice #News

DNA unwinding from histones
#Cancer research #DNA mutations #Epigenetics #Oncology

The ‘dark matter’ behind cancer

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong looks into recent research which may explain why cancers can become more aggressive. Researchers in London and Milan may have discovered why cancers can become more aggressive without relying only on DNA mutations. A lot of research to do… Read More

#Cancer Research #Exclusive Content

Mammography
#Breast cancer #Cancer research #European Commission #Gene mutation #Genetics / genomes #HER2 #Oncology

Drug approved for breast cancer with low levels of HER2 expression

Enhertu has been approved in the EU as the first HER2 directed therapy for patients with HER2 low metastatic breast cancer.  The drug is approved as monotherapy for adult patients who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within six… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Immune system #Immunotherapy #Oncology #Tumour biology #Tumours

Avoiding detection – the cancer cells evading the body’s natural defence

Listen to this article on the DDW Podcast: DDW Editor Reece Armstrong explores recent research looking into why cancer cells are so effective at avoiding the body’s immune system. Scientists may have discovered clues to why cancer cells can avoid the body’s immune system in a study conducted by researchers at… Read More

#Cancer Research #Exclusive Content

Skin cancer cells
#AI / data analytics / healthtech / informatics #Cancer #Cancer research #Cell #Melanoma #Oncology

Study reveals impact of cancer cell size on treatment response

Cancer cells can shrink or super-size themselves to survive drug treatment or other challenges within their environment, researchers have discovered.  Scientists at The Institute of Cancer Research, London, combined biochemical profiling technologies with mathematical analyses to reveal how genetic changes lead to differences in the size of… Read More

#Cancer Research #News

CAR-T therapy
#Cancer research #CAR-T #CARsgen Therapeutics #China #Collaboration #Huadong Medicine #Immunotherapy #Myeloma #Oncology #Partnership

Partners to commercialise CAR-T product in China

CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief… Read More

#Business & Investment #News

MRI showing glioblastoma
#Brain #Cancer research #Drug repurposing #Neuroscience #Oncology

FDA-approved drug sensitises brain cancer cells to radiotherapy

Researchers have discovered a clinical drug that sensitises glioblastoma (GBM) cells to radiotherapy and could replace the current standard of care.  Scientists from Korea and the US have unveiled the mechanism of radioresistance in GBM cells, identifying therapeutic targets to overcome radioresistance.  GBM is a… Read More

#Cancer Research #News

Cancer cell
#Bioprinting #Cancer research #Oncology #Organ-on-a-chip #Organoids #Precision medicine #Whitepaper

New whitepaper on trends in precision medicine: Cancer

Precision medicine uses information about an individual’s genes, proteins, and environment to prevent, diagnose, and treat diseases, including cancer. Differences in DNA, RNA, and protein can be identified in individual tissue samples, and even in individual cells. The massive data sets generated from this research have driven advances in data… Read More

#News

#Cancer research #Drug development #Drug discovery #Guide #Oncology #Precision medicine

Trends in precision medicine: Cancer

This is an extraordinarily exciting time to be involved in precision medicine for cancer. This new whitepaper reviews some of the topics and trends in this emerging research area, including: 3D cultures: Spheroids and organoids Organoids in cancer research Tumour microenvironments Organ-on-a-chip and body-on-a-chip 3D bioprinting… Read More

#Resources

#Biologics #Cancer research #Cancer treatment #Immunology #Oncology

Biologics and living drugs: entering a new era of cancer treatment

This paid-for advertorial by Sphere Fluidics appeared in the SLAS 2023 Supplement, Volume 24 – Issue 1, Winter 2022/2023 Modern drug development has expanded from chemist-made substances to biologics and cell-based therapies. Despite the progress of the last two decades, we are only scratching the surface of what is possible and… Read More

#Cancer Research #Exclusive Content

Bacteria
#Bacteria #Cancer research #everImmune #Oncology #Phase I trial

Oncobiotic cancer drug could be a step forward for science

The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients.  The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. … Read More

#Cancer Research #News

#Avacta #Cancer research #Chemotherapy #Oncology #Phase I trial #Precision medicine

Early trial data confirms drug’s tumour targeting potential

Cancer drug AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation Phase I clinical trial.   Additionally, analysis of tumour biopsies obtained from six patients indicates that doxorubicin is being released within the tumour tissue, confirming the tumour… Read More

#Cancer Research #Editor's Choice #News

#Autoimmune disease #Cancer research #Clinical trial #Fibrosis #Immunotherapy #Oncology

First-line clinical trial marks a turning point in drug development 

Genoscience Pharma, a clinical-stage biotech company developing lysosomotropic drug candidates for the treatment of cancer, fibrosis and auto-immune diseases through autophagy modulation has launched the ABE-LIVER study, along with trial sponsor Grenoble University Hospital.  The trial   This Phase IIb clinical trial will focus on first-line… Read More

#Cancer Research #News